"Further, the Company will continue to leverage th
Post# of 148279
(Total Views: 632)
Posted On: 11/22/2022 8:56:49 PM
Quote:
"Further, the Company will continue to leverage the performance of leronlimab in these and other studies to advance leronlimab in other HIV-related, non-alcoholic steatohepatitis (NASH), and oncology indications – where compelling data has been generated – that may benefit a greater number of patients and result in significant shareholder value creation. For example, the Company plans to continue to pursue other underserved HIV-related indications, where it can potentially be first to market. "
from the 10/28/22 Press Release:
CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues
https://www.cytodyn.com/investors/news-events...or-hiv-mdr
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼